Transdigm Group INC Form 4 insider transactions

TransDigm Group director Robert J. Small exercised stock options and subsequently sold 4,700 shares of common stock for over $6 million on December 10, 2025.

TransDigm Group Director Robert J. Small reported the sale of 90,953 shares of common stock for approximately $121.4 million.

TransDigm Group Director Kevin M Stein exercised stock options and subsequently sold a portion of the acquired common stock through a pre-arranged trading plan.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, exercised stock options and subsequently sold a portion of his common stock holdings under a 10b5-1 plan.

TransDigm Group Director Kevin M. Stein exercised stock options and subsequently sold an equal number of shares through a pre-arranged 10b5-1 plan.

TransDigm Group Director Kevin Stein exercised stock options and subsequently sold a portion of the acquired shares for a significant profit under a Rule 10b5-1 plan.

TransDigm Group Director Michael Graff has filed a Form 4 indicating a planned future gift of 340 shares of common stock to a trust on November 21, 2025, under a Rule 10b5-1 plan.

TransDigm Group Director Kevin M. Stein executed a pre-planned sale of 230 common shares following an option exercise, as disclosed in a recent SEC Form 4 filing.

TransDigm Group Director Kevin Stein exercised stock options and subsequently sold an equivalent number of shares through a pre-planned trading arrangement.

TransDigm Group Director Kevin Stein exercised stock options and subsequently sold an equal number of shares under a pre-arranged plan.

TransDigm Co-COO Joel Reiss exercised 3,900 options at $284.97 and sold the resulting shares via a Rule 10b5-1 plan, reducing direct holdings to 3,600 shares.

TransDigm Group's President and CEO, Michael Lisman, acquired 1,954 shares of common stock totaling approximately $2.6 million through a trust.

TransDigm Group Director W. Nicholas Howley exercised stock options and subsequently sold a portion of his common stock holdings through a pre-arranged 10b5-1 plan.

TransDigm Group Director David Barr was granted 518 stock options with an exercise price of $1,291.97, vesting over five years based on performance targets.

TransDigm Group Director Jane M. Cronin was granted 518 performance-based stock options with an exercise price of $1,291.97, vesting over five years.

TransDigm Group Inc. director Michael Graff was granted 518 stock options with an exercise price of $1,291.97, exercisable over five years starting September 30, 2026, contingent on performance targets.

TransDigm Group Director Sean Hennessy was granted 518 stock options with an exercise price of $1,291.97, exercisable over five years starting September 30, 2026, contingent on performance targets.

TransDigm Group Director W. Nicholas Howley was granted 518 stock options with a $1,291.97 exercise price, vesting over five years based on performance targets.

TransDigm Group Director Gary McCullough received 518 stock options with a $1,291.97 exercise price, vesting over five years based on performance targets.

TransDigm Group Director Peter Palmer reported the acquisition of 518 stock options with a $1,291.97 exercise price, vesting over five years contingent on performance targets.

TransDigm Group Director Michele Santana was granted 518 stock options, exercisable over five years starting September 30, 2026, contingent on annual operating performance targets.

TransDigm Group Director Robert J. Small was granted 518 stock options with an exercise price of $1,291.97, vesting over five years contingent on performance targets.

TransDigm Group Director Kevin Stein was granted 518 stock options with an exercise price of $1,291.97, exercisable over five years starting September 30, 2026, contingent on performance targets.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, acquired 26,450 stock options with an exercise price of $1,291.97, exercisable over five years starting September 30, 2026.

TransDigm Group's General Counsel, Armani Vadiee, acquired 17,100 stock options with an exercise price of $1,291.97, exercisable over five years starting September 30, 2026.

TransDigm Group's Chief Financial Officer, Sarah Wynne, was granted 8,700 stock options with an exercise price of $1,291.97, exercisable in 2029 and 2030.

TransDigm Group's Co-Chief Operating Officer, Joel Reiss, was granted 9,700 stock options with an exercise price of $1,291.97, exercisable in 2029 and 2030.

TransDigm Group's President and CEO, Michael Lisman, was granted 79,603 stock options with an exercise price of $1,291.97, exercisable over future years subject to performance targets.

TransDigm Group's Co-Chief Operating Officer, Patrick Joseph Murphy, exercised stock options and subsequently sold a portion of the acquired common stock.

TransDigm Group Director Kevin Stein executed a pre-planned sale of 700 common shares after exercising stock options.